Medinet Co, Ltd And MaxCyte, Inc. Initiate Collaboration For Novel Cancer Immuno-Cell Therapy

GAITHERSBURG, Md. & YOKOHAMA, Japan--(BUSINESS WIRE)--Aug. 17, 2006--MaxCyte, Inc. and Medinet Co., Ltd. announced today the signing of a collaboration agreement. Under the agreement MaxCyte will optimize its proprietary cell loading system for the development of Medinet's novel cancer immuno-cell therapy and implementation in a closed-system manufacturing process at Medinet's four cell processing centers in Japan. MaxCyte and Medinet have also agreed to key terms for a commercial license to MaxCyte's cell loading system to support clinical studies and commercialization of Medinet's immunotherapy product.